COMPANY PROFILE

OVERVIEW

Company
Rhelixa, Inc.
Office / Lab
5F KDX Ginza East Bldg., 3-7-2, Chuo-ku, Irifune, Tokyo, Japan.
Foundation
Feb. 2015
business
Omics research and consulting services
Development and operation of cloud-based services
Certification
JIS Q 27001:2014(ISO/IEC 27001:2013) MSA-IS-612
PARTNER








BUSINESS DATAas of Mar. 2023
Company
188company
Institute
275institute
Project
5348 project
MEMBER
MANAGEMENT

Representative Director, CEO
Tomoyuki Matsuno
After graduating from Yokohama National University, Tomoyuki joined Mitsubishi Corporation, where he was in charge of global sales and trading of derivatives products. Then worked for a U.S. trading company before becoming CEO of Rhelixa.

Director, COO
Takao Uchikai
Takao Uchikai holds a Ph.D. in Life Sciences from Tokyo Metropolitan University. Takao worked as a Next Generation Sequencing Lab Manager at Eurofin Genomics, Inc. and established genetic testing and bacterial flora testing at Anicom.

Director, CTO (Founder)
Ryo Nakaki
Ryo Nakaki holds a Ph.D. in Engineering from Department of Genome Science, Research Center for Advanced Science and Technology, Tokyo University. Ryo specializes in the analysis of large-scale omics data, especially epigenomic analysis. Ryo is a councilor of the Japanese Society of Anti-Aging Medicine.

General Manager, Administration Dept.
Ryota Kamiya
After graduating from Yokohama National University, Ryota joined Nippon Life Insurance Company, where he was engaged in corporate planning and management of group companies in the Asset Management Division. After joining Rhelixa,He reformed the company's internal systems and management infrastructure to take the company public.
ADVISER
Yasuharu Kanki (M.D., Ph.D.)
Graduated from Kyoto University School of Medicine (M.D.). Obtained a Ph.D. from the Laboratory for Systems Biology and Medicine (LSBM) at the University of Tokyo's Research Center for Advanced Science and Technology. Has experience studying at the National Institutes of Health (NIH). Has numerous research publications on vascular epigenomics.
Yukihiro Maru (Ph.D.)
Established Leave a Nest Co., Ltd. in 2002. Engaged in the "knowledge production industry," creating new businesses by combining technologies and knowledge from various fields. Building one of the largest deep tech ecosystems in Asia, and working on solving global-scale challenges. Involved in the launch of numerous deep tech ventures, including Euglena Co., Ltd.
Co-authored Papers
G3 (Bethesda). 2022 Jul 1:jkac166. doi: 10.1093/g3journal/jkac166. Online ahead of print.
Nat Commun. 2021 Dec 2;12(1):7045. doi: 10.1038/s41467-021-27321-5.
Sci Rep. 2021 Sep 21;11(1):18687. doi: 10.1038/s41598-021-98344-7.
Sci Signal. 2021 Jan 26;14(667):eabb3616. doi: 10.1126/scisignal.abb3616.
EMBO J. 2020 Mar e103949. doi.org/10.15252/embj.2019103949
Cell Rep. 2019 Oct 1;29(1):162-175.e9. doi: 10.1016/j.celrep.2019.08.086.
G3 (Bethesda). 2022 Jul 1:jkac166. doi: 10.1093/g3journal/jkac166. Online ahead of print.
Nat Commun. 2021 Dec 2;12(1):7045. doi: 10.1038/s41467-021-27321-5.
Sci Rep. 2021 Sep 21;11(1):18687. doi: 10.1038/s41598-021-98344-7.
Sci Signal. 2021 Jan 26;14(667):eabb3616. doi: 10.1126/scisignal.abb3616.
EMBO J. 2020 Mar e103949. doi.org/10.15252/embj.2019103949
Cell Rep. 2019 Oct 1;29(1):162-175.e9. doi: 10.1016/j.celrep.2019.08.086.